Introduction
Recent advances in biotechnology are leading to the development of many new medical tests. Tests can be used for various purposes including diagnosis, prognosis, risk prediction and disease screening. In parallel, statistical methodology for evaluating these tests has received much attention. Two recent books on the subject are references [1] and [2] . Vanrous measures can be used to quantify test accuracy. Frequently ulsed measuLres for binary tests are the sensitivity and specificity and the positive and negative predictive values. Let D = I diseasedj denote an individual's disease status and X = {test positivel contain the results of a diiagrnostic test. Although we use terminology for diagnostic testing where the predicted outcome is "presence of disease", as noted above other binary outcomes, such as future occurrence of an event, would be relevant for non-diagnostic tests. The sensitivity, P(X = ID = 1), and the specificity, P(X = OID = 0), assess the probability of a correct test result conditional on disease status. T'hey determine the extent to which the test accurately reflects presence or absence of disease and are often used in the early stages of test developimient [2] [3] [4] . On the other hand, the positive predictive value, P(D = OjX2 = 0). Because the predictive values depend on the prevalence of disease, P(D = 1), naively estimating them from a stLudy where P(D = 1 sampled) 0 P(D = 1) will restult in biased estimates. For this reason, we assume throughout that data are observed from a cross-sectional cohort design where D, X1 and X2 are sampled jointly.
Ihere are many situations where we might want to compare predictive values of two tests. Several authors have argued that the predictive values have greater clinical relevance than the sensitivity and specificity and are more directly applicable in patient care [4] [5] [6] . Consider 
National Cystic Fibrosis Patient Registry data
For illustrative purposes, the methodology developed in this paper will be applied to data from the 1996 Cystic Fibrosis Founldation National Registry. We have previously analyzed this data and describe it in greater detail in [8] . Here the two "diagnostic tests" we wish to compare are actually risk fiactors. In this context, presence of a risk factor is equated to testing positive. Further, these prognostic factors are sought to predict a future event, not to diagnose a current condition. As noted earlier, although the context differs from that of traditional diagnostic testing we see that the statistical framework is the same. Finally, in this example we might ultimately be interested in using a combination of the two risk factors, especially since the second risk factor is an observed event that makes no new requirements of a patient. For the purposes of demonstrating our methodology, t-hough, we take the simpler scenario of considering the two risk factors as two separate "tests".
Estimating the relative predictive values
Let Xi hold the result of test j, j = 1, 2. Its positive predictive value is P1PVx; = P(D = ljX, = 1) and negative predictive value is NPVXI = P(D = OIXj = 0). 1.35, 1.38) , respectively. In contrast, Figure 1 ShOWS the joint 90% confidence region for (rPPV, irNPV). In both cases the rPPV and rNPV are bounded well away fronm one indicatinig that 1995 pulmonlary exacerbation does a significantly better job of predicting 1996 pulmonary exacerbation.
Sample size formulas
The confidence intervals in (3) and (4) By exponentiating (3) and (4) we obtain upper and lower confidence limits for rPPV and rNPV.
A 100(1 -a)% elliptical confidence region for (rPPV, rNPV) is the set of (rI'PP, rNPV) such that clog rPPV -log rPPV 1 E log rPPV -log rPPV 1 WVe conducted a small simulation study to determine how well the formnula given in (6) worked in this examiple. Data was first simulated for 428 subjects under the null hypothesis, rejecting Ho3 if the lower limit of the confidence interval for log rPPV was greater than 0, and this process was repeated 1000 times. WVe then generated data under the alternative hypothesis, fixing y = 1.2, and repeated the same steps. (We generated data in the same way as described in Leisenring et al. [7] .) Under (7) Notice that because we have used observed data to estimate the variances in the confidence interval construction, the sample size formulas use standard errors that are calculated under the null hypothesis. Both of these sample size formulas require specification not only of a predictive value for the second test, a threshold value 6 under the null hypothesis and an assumed value for the rPPV under the alternative hypothesis, but of some additional probabilities as well. lntuitively, the probabilities of test positivity, P(X1 -1) and P(X-, = 1), and correlation between the tests enter iInto the variances of rPPV and rNPV. Then et P is the ratio of the odds of disease given a positive resLlt for the first test compared to the odds of disease given a positive result for the second test. If instead we use the natural logarithm as the link f:unction, e ' is the relative positive predictive value. Although both scales of coimparison are valid, ouLr focus is on the relative predictive values in part because we feel they are more easily interpreted thain odds ratios. Note also that the estimates of the rPPV and rNPV obtainied froim these models are identical to the estimates obtaiined using the formulas in Section 3. The standard error estimates can differ between the two methods, at least in finite samples. Simulation studies (not presented) suggest that these differences are negligible.
These are marginal models, although not in the usual sense. The miore familiar marginal models developed by Liang and Zeger [10] Fitting models (8) and (9) to the CF data using a log link function, we estimate the rPPV comparing 1995 pulmonary exacerbation to P. aeruginosa is 1.22 with a 90% confidence interval of (1.15, 1.34). We estimate the rNPV to be 1.37 with a 90% confidence interval of (1.35, 1.38). 
Discussion
In this paper we have developed a new way of comparing the predictive values of two tests that are assessed using a paired study design. It involves directly estimating the rPPV and rNPV and using analytic variance estimates. It results in estimates that are the same as those of Leisenring et al. [7] when a log link function g is used. 
